The anti-sclerostin antibody, romosozumab [6,7], and anti-RANKL antibody, denosumab [58,59], are now widely used for osteoporosis therapy; however, antibody drugs are still expensive for a large number of patients worldwide. This evidence concerns the gene TNFSF11 and osteoporosis.